Previous 10 | Next 10 |
home / stock / rhhby / rhhby articles
On Thursday, Roche Holdings AG (OTC:RHHBY) said that the Phase 2/3 SKYSCRAPER-06 study of tiragolumab plus Tecentriq (atezolizumab) and chemotherap...
On Wednesday, the FDA approved Epkinly (epcoritamab-bysp) as the first and only T-cell-engaging bispecific antibody administered subcutaneousl...
Roche (OTC: RHHBY) announced that the European Commission has granted marketing authorization to the subcutaneous formulation of relapsing mul...
Gilead Sciences, Inc. (NASDAQ:GILD) witnessed a flurry of Wall Street speculation regarding its potential involvement in the obesity drug market. B...
Thursday, the FDA approved labeled indication for Sarepta Therapeutics Inc’s (NASDAQ:SRPT) Elevidys (delandistrogene moxeparvovec-rokl) to in...
Goldman Sachs has initiated coverage on Regenxbio Inc (NASDAQ:RGNX), citing the potential for the company’s gene therapy platform. The compan...
Halozyme Therapeutics (NASDAQ: HALO) announced that it has been granted a new patent in the EU that covers the ENHANZE rHuPH20 product, which ...
Italy’s antitrust regulator has initiated an investigation into several pharmaceutical giants, including Novartis AG (NYSE:NVS) and Roche Hol...
Renewed partnership combines best in class engineering capabilities with cutting edge science to accelerate the availability of new solutions for ...
News, Short Squeeze, Breakout and More Instantly...
Roche Holding Ltd ADR Company Name:
RHHBY Stock Symbol:
OTCMKTS Market:
Roche Holding Ltd ADR Website:
– More than 90% of patients had absence of DME after four years in a pre-specified exploratory endpoint – – People treated with Vabysmo sustained vision gains and anatomical improvements, with almost 80% receiving treatment at intervals of three or four months, in an ...
– After four weeks of treatment, CT-996 demonstrated clinically meaningful weight loss of -7.3% (weight loss in placebo -1.2%; p < 0.001) 1 – – Pharmacokinetic data supports a once-daily oral dosing regimen for CT-996 1 – – The safety ...
Remix Therapeutics™ Attains Near-Term Milestone from Roche Collaboration PR Newswire The collaboration leverages Remix's REMaster ™ platform to discover novel drugs for a diverse range of target classes Remix is eligible to receive up to ...